{"id":"NCT05646719","sponsor":"Ocuphire Pharma, Inc.","briefTitle":"Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia","officialTitle":"Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 3 Study of the Safety and Efficacy of Nyxol (Phentolamine Ophthalmic Solution 0.75%) as a Single Agent and With Adjunctive Low-Dose Pilocarpine Hydrochloride Ophthalmic Solution 0.4% in Subjects With Presbyopia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-12-22","primaryCompletion":"2023-10-11","completion":"2023-10-11","firstPosted":"2022-12-12","resultsPosted":"2025-06-03","lastUpdate":"2025-08-01"},"enrollment":333,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Presbyopia"],"interventions":[{"type":"DRUG","name":"Phentolamine Opthalmic Solution 0.75%","otherNames":["Nyxol"]},{"type":"OTHER","name":"Placebo","otherNames":["Phentolamine Ophthalmic Solution Vehicle"]},{"type":"DRUG","name":"Low dose pilocarpine","otherNames":["Pilocarpine","LDP"]},{"type":"OTHER","name":"Low dose pilocarpine vehicle","otherNames":[]}],"arms":[{"label":"Nyxol + low dose pilocarpine","type":"EXPERIMENTAL"},{"label":"Nyxol + low dose pilocarpine vehicle","type":"EXPERIMENTAL"},{"label":"Placebo + low dose pilocarpine","type":"EXPERIMENTAL"},{"label":"Placebo + low dose pilocarpine vehicle","type":"EXPERIMENTAL"},{"label":"Nyxol","type":"EXPERIMENTAL"},{"label":"Nyxol placebo","type":"EXPERIMENTAL"}],"summary":"The objectives of this study are:\n\nTo evaluate the safety and efficacy of Nyxol alone and with adjunctive low dose pilocarpine to improve distance-corrected near visual acuity (DCNVA) in subjects with presbyopia.","primaryOutcome":{"measure":"Percent of Subjects With â‰¥ 15 Letters of Improvement in Photopic Binocular DCNVA and With < 5 Letters of Loss in Photopic Binocular BCDVA in Nyxol-treated Subjects","timeFrame":"Baseline at 30 min post-LDP/vehicle comparing subjects treated with Nyxol + LDP to subjects treated with placebo + LDP vehicle at Visit 5 (Stage 2 Day 8)","effectByArm":[{"arm":"Nyxol + Low Dose Pilocarpine","deltaMin":27,"sd":null},{"arm":"Nyxol + Low Dose Pilocarpine Vehicle","deltaMin":31,"sd":null},{"arm":"Placebo + Low Dose Pilocarpine","deltaMin":16,"sd":null},{"arm":"Placebo + Low Dose Pilocarpine Vehicle","deltaMin":22,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":"<0.01"},{"comp":"OG000 vs OG003","p":null}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":26,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":79},"commonTop":["Instillation site irritation","Headache","Instillation site erythema","Conjunctival hyperemia","Vision blurred"]}}